Cidara Therapeutics Stock Net Income
| CDTX Stock | USD 19.59 0.90 4.82% |
Cidara Therapeutics fundamentals help investors to digest information that contributes to Cidara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cidara Stock. The fundamental analysis module provides a way to measure Cidara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cidara Therapeutics stock.
Cidara |
Cidara Therapeutics Company Net Income Analysis
Cidara Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cidara Therapeutics Net Income | (22.93 M) |
Most of Cidara Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cidara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cidara Therapeutics reported net income of (22.93 Million). This is 106.72% lower than that of the Biotechnology sector and 132.74% lower than that of the Health Care industry. The net income for all United States stocks is 104.02% higher than that of the company.
Cidara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cidara Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics of similar companies.Cidara Therapeutics is currently under evaluation in net income category among its peers.
Cidara Fundamentals
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 8.26 M | ||||
| Shares Outstanding | 7.05 M | ||||
| Shares Owned By Insiders | 4.70 % | ||||
| Shares Owned By Institutions | 51.86 % | ||||
| Number Of Shares Shorted | 64.58 K | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 2.44 X | ||||
| Revenue | 63.91 M | ||||
| Gross Profit | (11.23 M) | ||||
| EBITDA | (24.36 M) | ||||
| Net Income | (22.93 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 4.88 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | (1.81) X | ||||
| Cash Flow From Operations | (22.43 M) | ||||
| Short Ratio | 3.88 X | ||||
| Earnings Per Share | (23.90) X | ||||
| Target Price | 27.33 | ||||
| Number Of Employees | 69 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 131.7 M | ||||
| Total Asset | 67.03 M | ||||
| Retained Earnings | (441.43 M) | ||||
| Working Capital | (6.56 M) | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 67.03 M |
About Cidara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cidara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.